SHANGHAI – Clinical-stage immuno-oncology company, Beigene Co. Ltd., of Beijing, has announced its intention to raise $100 million on Nasdaq. A member of the small but growing group of rising biotech stars in China, Beigene filed IPO intentions to sell American depository shares with the SEC as an emerging growth company with reduced filing requirements. Pricing terms were undisclosed.